119 related articles for article (PubMed ID: 7987978)
1. Cyclophosphamide, cisplatin, and carmustine: pharmacokinetics of carmustine following multiple alkylating-agent interactions.
Jones RB; Matthes S; Kemme D; Dufton C; Kernan S
Cancer Chemother Pharmacol; 1994; 35(1):59-63. PubMed ID: 7987978
[TBL] [Abstract][Full Text] [Related]
2. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics.
Cagnoni PJ; Matthes S; Day TC; Bearman SI; Shpall EJ; Jones RB
Bone Marrow Transplant; 1999 Jul; 24(1):1-4. PubMed ID: 10435726
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer.
Jones RB; Matthes S; Dufton C; Bearman SI; Stemmer SM; Meyers S; Shpall EJ
Breast Cancer Res Treat; 1993; 26 Suppl():S11-7. PubMed ID: 8400329
[TBL] [Abstract][Full Text] [Related]
4. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine.
Jones RB; Matthes S; Shpall EJ; Fisher JH; Stemmer SM; Dufton C; Stephens JK; Bearman SI
J Natl Cancer Inst; 1993 Apr; 85(8):640-7. PubMed ID: 8468721
[TBL] [Abstract][Full Text] [Related]
5. Severe depletion of cellular thiols and glutathione-related enzymes of a carmustine-resistant L1210 strain associates with collateral sensitivity to cyclophosphamide.
Institoris E; Tretter L; Gaál D
Cancer Chemother Pharmacol; 1993; 33(1):85-8. PubMed ID: 8269595
[TBL] [Abstract][Full Text] [Related]
6. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
Petros WP; Broadwater G; Berry D; Jones RB; Vredenburgh JJ; Gilbert CJ; Gibbs JP; Colvin OM; Peters WP
Clin Cancer Res; 2002 Mar; 8(3):698-705. PubMed ID: 11895898
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and immediate effects of high-dose carmustine in man.
Henner WD; Peters WP; Eder JP; Antman K; Schnipper L; Frei E
Cancer Treat Rep; 1986 Jul; 70(7):877-80. PubMed ID: 3719578
[TBL] [Abstract][Full Text] [Related]
9. Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. III. Biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNU.
Schabel FM; Trader MW; Laster WR; Shaddix SC; Brockman RW
Cancer Treat Rep; 1976 Sep; 60(9):1325-33. PubMed ID: 1016968
[TBL] [Abstract][Full Text] [Related]
10. Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide.
Teicher BA; Crawford JM; Holden SA; Lin Y; Cathcart KN; Luchette CA; Flatow J
Cancer; 1988 Oct; 62(7):1275-81. PubMed ID: 2843275
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine.
Ren S; Slatterly JT
AAPS PharmSci; 1999; 1(3):E14. PubMed ID: 11741210
[TBL] [Abstract][Full Text] [Related]
12. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease.
Reece DE; Nevill TJ; Sayegh A; Spinelli JJ; Brockington DA; Barnett MJ; Klingemann HG; Connors JM; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Fairey RN; O'Reilly SE; Phillips GL
Bone Marrow Transplant; 1999 Jun; 23(11):1131-8. PubMed ID: 10382952
[TBL] [Abstract][Full Text] [Related]
13. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
Peters WP; Ross M; Vredenburgh JJ; Meisenberg B; Marks LB; Winer E; Kurtzberg J; Bast RC; Jones R; Shpall E
J Clin Oncol; 1993 Jun; 11(6):1132-43. PubMed ID: 8501500
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
Buckner JC; Ballman KV; Michalak JC; Burton GV; Cascino TL; Schomberg PJ; Hawkins RB; Scheithauer BW; Sandler HM; Marks RS; O'Fallon JR; ;
J Clin Oncol; 2006 Aug; 24(24):3871-9. PubMed ID: 16921039
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects.
Jones RB; Stockerl-Goldstein KE; Klein J; Murphy J; Blume KG; Dansey R; Martinez C; Matthes S; Nieto Y
Biol Blood Marrow Transplant; 2004 Apr; 10(4):276-82. PubMed ID: 15077226
[TBL] [Abstract][Full Text] [Related]
17. The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU.
Levin VA; Stearns J; Byrd A; Finn A; Weinkam RJ
J Pharmacol Exp Ther; 1979 Jan; 208(1):1-6. PubMed ID: 759602
[TBL] [Abstract][Full Text] [Related]
18. Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
Horvath Z; Höchtl T; Bauer W; Fritzer-Szekeres M; Elford HL; Szekeres T; Tihan T
Cancer Chemother Pharmacol; 2004 Aug; 54(2):139-45. PubMed ID: 15133626
[TBL] [Abstract][Full Text] [Related]
19. Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model.
Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE
J Clin Invest; 1987 May; 79(5):1524-8. PubMed ID: 3033027
[TBL] [Abstract][Full Text] [Related]
20. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
